Overview Leading endpoint security companies now rely heavily on AI and automation for faster threat detection.Cloud-based ...
Jyong Biotech (MENS) announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8, PCP. The Company has completed the statistical analysis of the primary ...
The endpoint security market is poised for growth due to rising cyber threats and regulatory demands. Opportunities emerge ...
In the business landscape today, remote work is a standard. But as teams move beyond the office, keeping data safe becomes ...
The MCS-8 (PCP) Phase II study was a randomized, placebo-controlled trial conducted across 20 hospitals in Taiwan with participation from over 130 urologists—representing more than one-tenth of all ...
The Cavli Hubble™ Messaging Service is built on a dual-channel architecture designed to separate modem-management ...
Alto Neuroscience, Inc.'s innovative approach to CNS disorder treatment and 2026 clinical milestones. Click here to find out ...
Gilead has reported that its phase 3 ASCENT-07 trial evaluating Trodelvy (sacituzumab govitecan-hziy) as a first-line ...
Praxis Precision Medicines, Inc. is upgraded to Strong Buy, driven by pipeline progress and positive Phase 3 data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback